KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Gains from Investment Securities (2016 - 2024)

Nektar Therapeutics (NKTR) has 15 years of Gains from Investment Securities data on record, last reported at -$7.6 million in Q4 2024.

  • For Q4 2024, Gains from Investment Securities changed N/A year-over-year to -$7.6 million; the TTM value through Dec 2024 reached $76000.0, down 97.14%, while the annual FY2024 figure was $76000.0, 97.14% down from the prior year.
  • Gains from Investment Securities reached -$7.6 million in Q4 2024 per NKTR's latest filing, down from $2.1 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.7 million in Q4 2021 and bottomed at -$7.6 million in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $227789.5, with a median of $287000.0 recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: soared 522.46% in 2021, then crashed 2014.29% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at -$1.6 million in 2020, then skyrocketed by 522.46% to $6.7 million in 2021, then crashed by 105.52% to -$372000.0 in 2022, then tumbled by 1376.88% to -$5.5 million in 2023, then tumbled by 38.97% to -$7.6 million in 2024.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$7.6 million in Q4 2024, $2.1 million in Q3 2024, and $2.6 million in Q2 2024.